Parkinson’s disease is the second most common neurodegenerative disorder. It is characterized by misfolded alpha-synuclein deposits and dopaminergic neuron death, which lead to progressive motor impairment and disability. Despite extensive efforts, there are no disease-modifying therapies available for Parkinson’s disease or related “alpha-synucleinopathies.” Glia may represent a source of untapped therapeutic potential.
In this webinar sponsored by BioLegend, Abby Olsen, Associate Neurologist at Brigham and Women’s Hospital, will discuss how an innovative Drosophila model helps explore the genetic contribution of glia to Parkinson’s disease pathogenesis. She will review how forward genetic screens identify novel glial genes and potential therapeutic targets for downstream investigation in mammalian systems and patients.
Topics to be covered
A Drosophila model of neurodegenerative alpha-synucleinopathies
The role of alpha-synuclein in glia
The unique transcriptional signature of alpha-synuclein in glia in Parkinson’s disease
The pathogenic effects and mechanisms of Parkinson’s disease candidate genes when expressed in the glia
Genetic screens to identify novel glial genes and potential therapeutic targets
Thursday, September 17, 2020
12:00 - 1:00 PM, Eastern Standard Time
Abby Olsen, MD, PhD Associate Neurologist Brigham and Women’s Hospital Instructor in Neurology Harvard Medical School
Unpacking the Genetic Contribution of Glia to Parkinson’s Disease
The Scientist c/o LabX Media Group 1000 N West Street, Suite 1200, Wilmington, Delaware, United States, 19801 Toll Free: 888.788.0328 | Phone: 705.528.6888 Email: firstname.lastname@example.org